BANK VONTOBEL AG | Market Closed - Swiss Exchange 08:50:00 27/06/2024 pm IST | ||
| 103 CHF | +0.10% |
|
| Current year | +2.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 103 | +0.10% |
Delayed Quote Swiss Exchange
Last update June 27, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| RMACUV | |
| ISIN | CH1293293978 |
| Date issued | 20/10/2023 |
| Strike | 677.7 kr |
| Maturity | 22/04/2025 (297 Days) |
| Parity | 0.68 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 103.3 CHF |
|---|---|
| Lowest since issue | 99.4 CHF |
| Spread | 8 CHF |
| Spread % | 0.77% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- RMACUV Certificat
